前言近些年來,肝細胞癌（hepatocellular carcinoma,HCC）發(fā)病率在局部地區(qū)有上升趨勢,是全球第三大癌癥死因。世界上約75%-80%的HCC患者為亞太居民,這些患者HCC多由于HBV和/或HCV導致的肝硬化所致。中國大陸HCC患者眾多,每年發(fā)病率約為28/10萬,死亡率為26/10萬。而且,HCC起病隱匿,患者就診時病情多已屬中晚期,患者長期預后差。HCC腫瘤分期決定著患者的治療方式和遠期療效。巴塞羅那肝癌分期系統(tǒng)（Barcelona Clinical Liver Cancer,BCLC）備受國內外學者推崇,是唯一被美國肝病研究協(xié)會（American Association for the Study of Liver Diseases,AASLD）和歐洲肝臟研究協(xié)會（European Association for the Study of the Liver,EASL）雙重推薦的HCC分期系統(tǒng)。BCLC分期系統(tǒng)僅推薦A期HCC患者行肝切除術,患者應符合Milan標準:（a）僅有單個腫瘤且腫瘤直徑<5cm,或≤3個結節(jié),且最大腫瘤直徑≤3cm;（b）肝功能... 

【文章來源】：廣西醫(yī)科大學廣西壯族自治區(qū)

【文章頁數(shù)】：116 頁

【學位級別】：博士

【部分圖文】：

大/多結節(jié)HCC患者行肝切除術后5年總生存率和無病生存率

患者術后 5 年總生存率和無瘤生存率均隨年份顯著提高（P<0.001，圖 1-2和圖 1-3）。圖1-2. 大/多結節(jié)HCC 患者行肝切除術后 5年總生存率隨時間變化情況Fig 1-2. Five-year survival trend of patients with large/multinodular hepatocellular carcinoma after surgery圖1-3. 大/多結節(jié)HCC 患者行肝切除術后 5年無病生存率隨時間變化情況Fig 1-3. Five-year disease-free survival trend of patients with large/multinodular hepatocellular carcinomaafter surgery

圖1-2. 大/多結節(jié)HCC 患者行肝切除術后 5年總生存率隨時間變化情況Fig 1-2. Five-year survival trend of patients with large/multinodular hepatocellular carcinoma after surgery圖1-3. 大/多結節(jié)HCC 患者行肝切除術后 5年無病生存率隨時間變化情況Fig 1-3. Five-year disease-free survival trend of patients with large/multinodular hepatocellular carcinomaafter surgery

【參考文獻】：
期刊論文
[1]肝細胞癌肝切除術的爭議[J]. 鐘鑒宏,游雪梅,黎樂群.  中國普通外科雜志. 2017(01)
[2]肝切除術治療大/多結節(jié)或大血管侵犯肝細胞癌效果的薈萃分析[J]. 李威,游雪梅,黎樂群,鐘鑒宏.  中華醫(yī)學雜志. 2015 (38)
[3]肝細胞癌根治性術后的治療選擇[J]. 鐘鑒宏,黎樂群.  中華臨床醫(yī)師雜志(電子版). 2013(23)
[4]Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy[J]. Yang Ke,Liang Ma,Xue-Mei You,Sheng-Xin Huang,Yong-Rong Liang,Bang-De Xiang,Le-Qun Li.  Cancer Biology & Medicine. 2013(03)
[5]Report of incidence and mortality in China cancer registries, 2009[J]. Wanqing Chen,Rongshou Zheng,Siwei Zhang,Ping Zhao,Guanglin Li,Lingyou Wu,Jie He.  Chinese Journal of Cancer Research. 2013(01)
[6]Role of surgical resection for multiple hepatocellular carcinomas[J]. Sung Hoon Choi,Gi Hong Choi,Seung Up Kim,Jun Yong Park,Dong Jin Joo,Man Ki Ju,Myoung Soo Kim,Jin Sub Choi,Kwang Hyub Han,Soon Il Kim.  World Journal of Gastroenterology. 2013(03)
[7]原發(fā)性肝癌診療規(guī)范（2011年版）[J]. Ministry of Health of the People’s Republic of China.  臨床肝膽病雜志. 2011(11)
[8]Therapeutic options for intermediate-advanced hepatocellular carcinoma[J]. Zong-Ming Zhang, Jin-Xing Guo, Zi-Chao Zhang, Nan Jiang, Zhen-Ya Zhang, Li-Jie Pan, Department of General Surgery, Digestive Medical Center, The First Affiliated Hospital, School of Medicine, Tsinghua University, Beijing 100016, China.  World Journal of Gastroenterology. 2011(13)
[9]Hepatectomy in the treatment of very big primary liver cancer: report of 86 cases[J]. Jia-Mei Yang;Tong Kan;Han Chen;Meng-Chao Wu From the Eastern Hospital of Hepatobiliary Surgery, Second Military Medical University, Shanghai 200433 China.  Hepatobiliary & Pancreatic Diseases International. 2002(01)
[10]Stage Ⅱ surgical resection of hepatocellular carcinoma after TAE:a report of 38 cases[J]. WANG Jian Hua, LIN Gui △, YAN Zhi Ping, WANG Xiao Lin, CHENG Jie Ming and LI Mao Quan.  World Journal of Gastroenterology. 1998(02)



本文編號：3581066